Novartis Pharmaceuticals UK Ltd

Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Patient Information Leaflet last updated on the eMC: 08/11/2011
PIL Starlix 60mg, 120mg, 180mg film coated tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 08/11/2011 and displayed until Current
Reasons for adding or updating:
  • Change/addition of instructions for reconstitution and/ or administration
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to instructions about missed dose
  • Change to instructions about overdose
  • Change to storage instructions
  • Change to side-effects
  • Change to drug interactions
  • Change to information about drinking alcohol
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Change to MA holder contact details
Updated on 21/09/2009 and displayed until 08/11/2011
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 26/05/2005 and displayed until 21/09/2009
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 18/11/2002 and displayed until 26/05/2005
Reasons for adding or updating:
  • Update to PIL

Active Ingredients/Generics

 
   nateglinide